Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

References for PMC Articles for PubMed (Select 19920098)


Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, Akporiaye E, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, Fox BA.

Curr Mol Med. 2009 Aug;9(6):673-82. Review.


IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.

Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL.

J Immunol. 2009 Aug 15;183(4):2475-83. doi: 10.4049/jimmunol.0900986. Epub 2009 Jul 27.


Role of arginine metabolism in immunity and immunopathology.

Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, Mantelli B, Bronte V, Zanovello P.

Immunobiology. 2007;212(9-10):795-812. Epub 2007 Nov 14. Review.


Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer.

Lubaroff DM, Konety B, Link BK, Ratliff TL, Madsen T, Shannon M, Ecklund D, Williams RD.

Hum Gene Ther. 2006 Feb;17(2):220-9. No abstract available.


Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.

Clin Cancer Res. 2005 May 1;11(9):3353-62. Erratum in: Clin Cancer Res. 2006 Jan 1;12(1):322.


Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, Nelson WG, Pardoll DM, Adler AJ.

Cancer Cell. 2005 Mar;7(3):239-49.


Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.

Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J.

J Immunol. 2005 Mar 15;174(6):3798-807.


Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.


Augmentation of T cell levels and responses induced by androgen deprivation.

Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED.

J Immunol. 2004 Nov 15;173(10):6098-108.


Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.

Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M, Suekane S, Matsuoka K.

Prostate. 2005 Apr 1;63(1):1-12.


Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG.

BJU Int. 2004 Aug;94(3):412-8.


A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P.

Br J Cancer. 2004 Aug 16;91(4):688-94.


Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.


Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM.

J Clin Oncol. 2004 Jun 1;22(11):2122-32.


Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM.

Clin Cancer Res. 2004 Feb 1;10(3):828-39.


Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI.

J Clin Oncol. 2003 Dec 1;21(23):4292-8.


Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ.

J Clin Oncol. 2003 Apr 1;21(7):1232-7. Erratum in: J Clin Oncol. 2004 Aug 15;22(16):3434.


Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J.

Prostate. 2002 Oct 1;53(2):109-17.


Technology evaluation: APC-8015, Dendreon.

Rini BI.

Curr Opin Mol Ther. 2002 Feb;4(1):76-9. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk